# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. ("Allarity"...
Allarity Therapeutics shares are trading lower by 27.6% during Monday's session. The company announced that it received a n...
On June 18, 2024, Allarity Therapeutics, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Staff (t...
- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved- On Track to Regain Compliance with All N...